JHVEPhoto Galapagos ( NASDAQ: GLPG ) shares traded higher in Europe on Friday after the U.S. Food and Drug Administration (FDA) greenlighted a Phase 1/2 trial for its CAR-T cell therapy, GLPG5101, in non-Hodgkin lymphoma, a cancer of white blood cells.
Named ATALANTA-1, the multicenter trial is already underway in Europe, and its early data have indicated GLPG5101’s potential in relapsed/refractory non-Hodgkin lymphoma (NHL), the Belgian biotech said. With the FDA clearance, the company can expand it in the U.S.
Phase 1 of ATALANTA-1 is designed to evaluate GLPG5101’s efficacy and safety to help investigators determine the recommended dose for the Phase 2 section. Phase 2 is designed to specify the objective response rate, a critical parameter for cancer drugs, as its primary objective. Its secondary objectives include overall survival, the “gold standard” for measuring the clinical benefits of a cancer therapy.
More on Galapagos Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript Galapagos pauses enrollment in Phase 1/2 study for GLPG5301 Galapagos downgraded at Raymond James on lack of business development Seeking Alpha’s Quant Rating on Galapagos Historical earnings data for Galapagos.